Player of the Week: Alli Vogel – The Bridgton News

Posted on by

Alli Vogel is a great role model and leader in both her words and her actions, on the field and in the classroom, says Lake Region varsity field hockey coach Pauline Webb.

She was injured during last years ski season and was not going to be cleared to play field hockey her senior year. She was the first to contact me for summer season and wanted to be part of the team as much as possible. She is my go-to player when I need to get a message to the team; I can trust that the message will go out promptly, Coach Webb said. She participated in practice as much as she was cleared to, and when I found out that I needed another goalie, I asked her if shed be willing to play goalie if her doctor cleared her for that position. She had a smile on her face when I asked her and a week or so later she messaged me and told me her doctor cleared her to play goalie.

Allis desire to play her senior year, her competitive spirit, her athletic abilities, and her coachability are the reasons she is picking up the new position so quickly and the reasons Coach Webb is pleased to recognize her as the Player of the Week.

In recognition of her strong work ethic, determination, commitment and good sportsmanship, Alli is this weeks Boosters and Hancock Lumber Player of the Week. Each week, a Lake Region athlete is recognized for his/her dedication (does more than what is asked), work ethic, coachability and academic good standing. Recipients receive a specially-designed t-shirt, sponsored by Hancock Lumber.

Player of the Week: Alli Vogel

Hometown: Bridgton

Year in School: Senior

Parents: Jen and Ryan Vogel

Sports you play: Field Hockey, alpine skiing and lacrosse

School groups/honors: National Honor Society, ASTRA, Interact and Math Team

Q. Why did you choose field hockey? I chose field hockey because my mom and grandmother played it and I wanted to try something new after playing soccer.

Q. What do you enjoy most about field hockey? I really love our team. We have a great atmosphere and were all so close with each other.

Q. How has competing in sports changed you as a person? Sports have helped me develop leadership skills, for example, I organized and led skills practices over this summer.

Q. During this period of Covid-19, what has been the most difficult adjustment? I had ACL surgery right at the beginning of this Covid-19 period and it was definitely very hard to adjust to not being able to be active or not playing a sport because Ive been a three-sport athlete since middle school.

Q. What is your most disappointing sports memory? Tearing my ACL my first run at Ski Racing States last year.

Q. How has sports prepared you for your future (be it career path or approach to life)? They have helped me gain time management skills to balance school and sports which will help me later in life.

Q. Name a coach who has made a difference in your life and in what way? Coach Whitney had a big impact on my life, from my freshman year through last year. Coach Whitney worked primarily with the defense, and she gave me the confidence that makes me the player that I am today.

Q. What are your future goals? I hope to attend college and major in Chemical Engineering and have a minor or concentration in bioengineering/biotechnology. I would also like to try to play field hockey or lacrosse in college.

See more here:
Player of the Week: Alli Vogel - The Bridgton News

Biogen partners with Gingko to develop platform – BioProcess Insider – BioProcess Insider

Posted on by

Biogen will use Gingko Bioworks mammalian cell programming platform to help advance its AAV-based vector manufacturing.

Under the terms of the agreement, Gingko will provide Biogen with access to its cell programming capabilities and platform.

Gingko will use its bioengineering resources and biomanufacturing space to enhance Biogens AAV production titers in its gene therapy manufacturing processes.

Image: iStock/metamorworks

Biogen will pay $5 million upfront, but Gingko has the potential to receive $115 million depending on research, development, and commercial milestones.

Biogen says that while AAV-based vectors carry the potential to treat different conditions and are used widely across the industry to develop gene therapies, the current manufacturing process is time-consuming and expensive, which makes it problematic to develop therapies for diseases that have large patient populations and require a high dose.

According to Biogen, Gingko will attempt to solve this challenge by using its mammalian cell programming platform (Bioworks4) to improve the efficacy of AAV-producing plasmid vectors and cell lines. In turn, potentially advancing Biogens novel gene therapies.

We are excited to collaborate with Biogen as they aim to develop treatments that may potentially slow, halt or cure neurological and neurodegenerative diseases and seek to enhance the industry standard for AAV manufacturing, said Jason Kelly, CEO of Ginkgo Bioworks.

Synthetic biology is leveraging the power of living cells to develop the next generation of therapeutics, everything from CAR-T, to CRISPR and gene therapies, which we believe will have a material impact on the lives of many.

This deal comes less than two weeks after Gingko Bioworks added large-scale protein capabilities outside the US through its acquisition of fungal platform technology firm Dutch DNA.

Visit link:
Biogen partners with Gingko to develop platform - BioProcess Insider - BioProcess Insider

Chitosan Derivatives Market 2020 to Expand at a CAGR of XX% by 2026: Analysis by Top Manufacturers, Product Type, Market Size & Growth, Focused…

Posted on by

Chitosan Derivatives Market report would come handy to understand the competitors in the market and give an insight into sales, volumes, revenues in the Chitosan Derivatives Industry & will also assists in making strategic decisions. The report also helps to decide corporate product & marketing strategies. It reduces the risks involved in making decisions as well as strategies for companies and individuals interested in the Chitosan Derivatives industry. Both established and new players in Chitosan Derivatives industries can use the report to understand the Chitosan Derivatives market.

In Global Market, the Following Companies Are Covered:

Get a Sample Copy of the Report @ https://www.360marketupdates.com/enquiry/request-sample/14867224

Analysis of the Market:

Chitosan is a linear polysaccharide composed of randomly distributed -(1-4)-linked D-glucosamine and N-acetyl-D-glucosamine. It is produced by basic (caustic soda) deacetylation reaction of chitin, the main component of fungi cell walls and insect or crustacean exoskeletons.

Chitosan derivatives can be used in various fields, like medical, health food cosmetics, water treatment, etc. Medical is the largest application of chitosan derivatives, with market share of 37.85% in 2015. Health food and cosmetics are also important applications of chitosan derivatives, due to the growing demand of life quality improvement.

Market Analysis and Insights: Global Chitosan Derivatives Market

The global Chitosan Derivatives market is valued at 40 million USD in 2020 is expected to reach 54 million USD by the end of 2026, growing at a CAGR of 4.4% during 2021-2026.

Global Chitosan Derivatives Market: Drivers and Restrains

The research report has incorporated the analysis of different factors that augment the markets growth. It constitutes trends, restraints, and drivers that transform the market in either a positive or negative manner. This section also provides the scope of different segments and applications that can potentially influence the market in the future. The detailed information is based on current trends and historic milestones. This section also provides an analysis of the volume of production about the global market and also about each type from 2015 to 2026. This section mentions the volume of production by region from 2015 to 2026. Pricing analysis is included in the report according to each type from the year 2015 to 2026, manufacturer from 2015 to 2020, region from 2015 to 2020, and global price from 2015 to 2026.

A thorough evaluation of the restrains included in the report portrays the contrast to drivers and gives room for strategic planning. Factors that overshadow the market growth are pivotal as they can be understood to devise different bends for getting hold of the lucrative opportunities that are present in the ever-growing market. Additionally, insights into market experts opinions have been taken to understand the market bette

Chitosan Derivatives Market Breakdown by Types:

Chitosan Derivatives Market Breakdown by Application:

Critical highlights covered in the Global Chitosan Derivatives market include:

The information available in the Chitosan Derivatives Market report is segmented for proper understanding. The Table of contents contains Market outline, Market characteristics, Market segmentation analysis, Market sizing, customer landscape & Regional landscape. For further improving the understand ability various exhibits (Tabular Data & Pie Charts) has also been used in the Chitosan Derivatives Market report.

Get a Sample Copy of the Report @ https://www.360marketupdates.com/enquiry/request-sample/14867224

Reasons for Buy Chitosan Derivatives Market Report:

In the end, Chitosan Derivatives Industry report provides the main region, market conditions with the product price,profit, capacity, production, supply, demand and market growth rateand forecast etc. This report also Present newproject SWOT analysis,investment feasibility analysis, andinvestment return analysis.

Contact Us:

Name: Mr. Ajay More

Email: [emailprotected]

Organization: 360 Market Updates

Phone: +14242530807 / + 44 20 3239 8187

Rock Drilling Jumbo Market Analysis and Forecast by Recent Trends, consumption by Regional data, Investigation and Growth, Developments in Manufacturing Technology and Growth Overview

Global Agricultural Equipment Rubber Track Market 2020 Segmentation and Analysis by Recent Trends, consumption by Regional data, Development, Investigation, Growth by to 2026

KVM Switch Market 2020: Top Companies, consumption by Regional data, Growth Overview and Investigation & Growth Factors Details by Regions, Types & Applications

Visit link:
Chitosan Derivatives Market 2020 to Expand at a CAGR of XX% by 2026: Analysis by Top Manufacturers, Product Type, Market Size & Growth, Focused...

Long-term COVID-19 containment will be shaped by strength and duration of natural, vaccine-induced immunity – YubaNet

Posted on by

September 22, 2020 New research suggests that the impact of natural and vaccine-induced immunity will be key factors in shaping the future trajectory of the global coronavirus pandemic, known as COVID-19. In particular, a vaccine capable of eliciting a strong immune response could substantially reduce the future burden of infection,according to a study by Princeton researcherspublished in the journal Science Sept. 21.

Much of the discussion so far related to the future trajectory of COVID-19 has rightly been focused on the effects of seasonality and non-pharmaceutical interventions [NPIs], such as mask-wearing and physical distancing,said co-first authorChadi Saad-Roy, a Ph.D. candidate in PrincetonsLewis-Sigler Institute for Integrative Genomics. In the short term, and during the pandemic phase, NPIs are the key determinant of case burdens. However, the role of immunity will become increasingly important as we look into the future.

Ultimately, we dont know what the strength or duration of natural immunity to SARS-CoV-2 or a potential vaccine will look like, explained co-first author Caroline Wagner, an assistant professor of bioengineering at McGill University who worked on the study as a postdoctoral research associate in thePrinceton Environmental Institute(PEI).

For instance, if reinfection is possible, what does a persons immune response to their previous infection do? Wagner asked. Is that immune response capable of stopping you from transmitting the infection to others? These will all impact the dynamics of future outbreaks.

The current study builds onPrinceton research published in Science May 18that reported that local variations in climate are not likely to dominate the first wave of the COVID-19 pandemic and included many of the same authors, who are all affiliated with theClimate Change and Infectious Diseaseinitiative funded by PEI and thePrinceton Institute for International and Regional Studies(PIIRS).

In the most recent paper, the researchers used a simple model to project the future incidence of COVID-19 cases and the degree of immunity in the human population under a range of assumptions related to how likely individuals are to transmit the virus in different contexts. For example, the model allows for different durations of immunity after infection, as well as different extents of protection from reinfection.The researchersposted online an interactive version of models predictionsunder these different sets of assumptions.

As expected, the model found that theinitial pandemic peak is largely independent of immunity because most people are susceptible. However, a substantial range of epidemic patterns are possible as SARS-CoV-2 infection and thus immunity increases in the population.

If immune responses are only weak, or transiently protective against reinfection, for example, then larger and more frequent outbreaks can be expected in the medium term, said co-authorAndrea Graham, professor ofecology and evolutionary biologyat Princeton and anassociated faculty member in PEI.

The nature of the immune responses also can affect clinical outcomes and the burden of severe cases requiring hospitalization, the researchers found. The key question is the severity of subsequent infections in comparison to primary ones.

Importantly, the study found that in all scenarios a vaccine capable of eliciting a strong immune response could substantially reduce future caseloads. Even a vaccine that only offers partial protection against secondary transmission could generate major benefits if widely deployed, the researchers reported.

Factors such as age and superspreading events are known to influence the spread of SARS-CoV-2 by causing individuals within a population to experience different immune responses or transmit the virus at different rates.Our models show that these factors do not affect our qualitative projections about future epidemic dynamics, saidBryan Grenfell, the Kathryn Briger and Sarah Fenton Professor of Ecology and Evolutionary Biology andPublic Affairsand an associated faculty member in PEI. Grenfell is a co-senior author on the paper withC. Jessica Metcalf, associate professor of ecology and evolutionary biology and public affairs and also a PEI associated faculty member.

As vaccine candidates emerge, and more detailed predictions of future caseloads with vaccination are needed, these additional details will need to be incorporated into more complex models,Grenfell said.

The study authors also explored the effect of vaccine hesitancy on future infection dynamics. Their model found that people who decline to partake in pharmaceutical and non-pharmaceutical measures to contain the coronavirus could nonetheless slow containment of the virus even if a vaccine is available.

Our model indicates that if vaccine refusal is high and correlated with increased transmission and riskier behavior such as refusing to wear a mask, then the necessary vaccination rate needed to reach herd immunity could be much higher, said co-authorSimon Levin, the James S. McDonnell Distinguished University Professor in Ecology and Evolutionary Biology and an associated faculty member in PEI. In this case, the nature of the immune response after infection or vaccination would be very important factors in determining how effective a vaccine would be.

When so much uncertainty in the underlying processes exists, it can be challenging to make accurate projections about the future, Grenfell said. We argue in this study that ultimately, a family of both simple and more complex models is the best way to proceed under these circumstances. Comparing the predictions of these models carefully and then coming up with a carefully averaged picture of the future as with weather prediction can be very helpful.

One of the main takeaways of the study is that monitoring population-level immunity to SARS-CoV-2, in addition to active infections, will be critical for accurately predicting future incidence.

This is not an easy thing to do accurately, particularly when the nature of this immune response is not well understood, said co-author Michael Mina, an assistant professor at the Harvard School of Public Health and Harvard Medical School. Even if we can measure a clinical quantity like an antibody titer against this virus, we dont necessarily know what that means in terms of protection.

Studying the effects of T-cell immunity and cross-protection from other coronaviruses are important avenues for future work, Metcalf said.

Additional authors on the paper includeRachel Baker, a PEI postdoctoral research associate; Sinead Morris, a postdoctoral research scientist at Columbia University who received her Ph.D. in ecology and evolutionary biology from Princeton; and Jeremy Farrar, director of the Wellcome Trust.

The paper, Immune life-history, vaccination, and the dynamics of SARS-CoV-2 over the next five years, was published online by Science Sept. 21. This work was supported by funds from the Natural Sciences and Engineering Research Council of Canada, the Life Sciences Research Foundation, the Cooperative Institute for Modelling the Earth System (CIMES) at Princeton University, the James S. McDonnell Foundation, the C3.ai Digital Transformation Institute, the National Science Foundation, the US Centers for Disease Control and Prevention, and Flu Lab.

More:
Long-term COVID-19 containment will be shaped by strength and duration of natural, vaccine-induced immunity - YubaNet

There’s a light at the end of the COVID-19 tunnel. Let’s make sure we all get there. – Anchorage Daily News

Posted on by

Eight months after Alaskas first COVID-19 case and seven months after in-person school ended in Anchorage, we stand at the darkest moment of the pandemic in our state. Case counts and positivity rates have skyrocketed. Hospitals and the health care workers who staff them are strained. The low death toll, long Alaskas signature accomplishment in its pandemic response, has begun to creep up. Rural communities that had escaped infection for many months are now feeling the brunt of the disease.

But in this darkest hour, we have at last been given the news so many of us have hoped for: COVID-19 vaccines are close to ready, and all evidence so far shows that the two most promising candidates are at least 90% effective. Thats a miracle, the kind of efficacy that could stamp out widespread COVID-19 infections worldwide. Its not too far into the realm of hyperbole to rank the development of a COVID-19 vaccine in the same realm as the Apollo Program that brought humankind to the moon. Never before has a disease been sequenced and a vaccine been developed so quickly. Never before has a vaccine been assembled using messenger RNA, a bioengineering feat that could herald a new era in combating disease. Never in our lifetimes has so much our health, our economy even and our ability to safely gather with other people hinged on a single technological advancement. This Thanksgiving, we ought all give thanks that so many have worked so hard to make it possible.

But its not here yet. Optimistic timetables hold that the vaccines could be approved for emergency use before the end of the year, but only for the highest-risk Americans. Perhaps 10 million doses will initially be available, and the logistical and technological hurdles in delivering the vaccine and keeping it supercooled so that it remains viable are immense. Once the vaccines are in full production, there will be tens of millions of doses produced every month, which could allow for most Americans to receive their shots by late spring or early summer. For those working to develop, transfer and administer the vaccine, there are hundreds of issues to overcome between now and then to make sure it can be rolled out safely and efficiently. For those of us waiting for the vaccine, theres only one significant issue to overcome, but its a doozy: Theres a lot of time between now and when most of us can be inoculated, and were heading in the wrong direction quickly with regard to the virus spread.

Theres less time between now and next summer than weve endured already under the changed world of the pandemic, but in that time, a quarter-million Americans have died. Were at our highest levels of infection yet, both in Alaska and the U.S. at large, and theres plenty of reason to believe that many people or more could die between now and when the vaccine allows us to achieve herd immunity. And every death from COVID-19 between now and then will be doubly tragic, as we now have a sense of how long we must hold out for the cure to arrive.

Given that reality, we must redouble our efforts to abide by the health practices set forth by national and state health authorities. Wear a mask in public. Maintain at least six feet of social distance between yourself and people outside your household bubble. Wash your hands frequently. Modify or cancel plans for holiday get-togethers to minimize risks though we may have to abide being apart from some of the people we love most this Thanksgiving and Christmas, doing so is the best way to ensure that well all be around for next years holidays.

The consequences if we dont get COVID-19 under control could be immense. Although the death rate for the virus is low, it rises when health care facilities are overwhelmed, reaching as high as 10% at the height of the early spikes in places like New York City and Italy. We cant afford to have that happen here, and Anchorage authorities have indicated they will institute more drastic closures of public facilities and businesses if such a situation is imminent. Many people, and many businesses, wont survive if that happens.

We know an end to COVID-19 is coming. We know the vaccines are effective, and we know there will be supply enough for everyone. But we must reach that point, and we must keep as many Alaskans alive as we possibly can on the way there. On the day we stamp out COVID-19 for good, we dont want to look back and realize we could have done more, could have kept more people we love from falling victim. We should be able to look back and recognize that we did everything we could.

Continued here:
There's a light at the end of the COVID-19 tunnel. Let's make sure we all get there. - Anchorage Daily News

The New York Academy of Sciences to host programs on the science and law of Lunar Exploration (Wednesday, December 9) and Bioengineering for Space…

Posted on by

Newswise New York, NY, December 7, 2020 The New York Academy of Sciences is hosting two programs on Space Exploration this week, with topics including legal agreements for off planet governance, bioengineering to make space travel safer for astronauts, and questions of bio-ethics related to interplanetary travel. Our Lunar Future, will be held on Wednesday evening, December 9, and a day-long technical symposium, Bioengineering for Space, will be held on Thursday, December 10.

Our Lunar Future Wednesday, December 9, 2020, 7 PM 8:30 PM EST

This program will discuss NASAs Artemis mission to orbit and then land on the lunar surface. Participants will explore scientific goals, and how establishing a more permanent human presence at the moon may serve as a stepping-stone to Mars. Speakers will also discuss how we establish international legal agreements off-planet.

The panelists will be:

This program will be moderated by Kari Fischer, PhD, New York Academy of Sciences.

For more information, please see: https://www.nyas.org/events/2020/webinar-our-lunar-future/.

Bioengineering for Space Thursday, December 10, 2020; 11:15 AM 4:40 PM EST.

This symposium will present research on gene editing and synthetic biology that may be used to overcome human limitations during long term spaceflight. The keynote speaker will be Anousheh Ansari of the XPRIZE Foundation.

Leading scientists will be speaking on topics that include:

The symposium will also feature panel discussions on questions of bio-ethics raised by space research and space travel. Will it be ethical to change the human genome to increase resistance to radiation and other hazards in space? Who gets to make decisions about space travel, acceptable risk, and the privatization of space? What responsibilities do scientists and astronauts have to avoid altering the genetic environment of lands we may seek to inhabit?

Speakers will also include: Martine Rothblatt, PhD, JD, MBA, United Therapeutics; Mark Weyland, MS, NASA; R. Alta Charo, JD, University of Wisconsin Law School; Eliza Strickland, IEEE Spectrum; and John Rummel, PhD, Friday Harbor Partners, LLC.

This program will be moderated by Kari Fischer, PhD, New York Academy of Sciences.

For more information, please see: https://www.nyas.org/events/2020/webinar-bioengineering-for-space/

ABOUT THE NEW YORK ACADEMY OF SCIENCES The New York of Academy of Sciences is an independent, not-for-profit organization that since 1817 has been committed to advancing science for the benefit of society. With more than 20,000 Members in 100 countries, the Academy advances scientific and technical knowledge, addresses global challenges with science-based solutions, and sponsors a wide variety of educational initiatives at all levels for STEM and STEM related fields. The Academy hosts programs and publishes content in the life and physical sciences, the social sciences, nutrition, artificial intelligence, computer science, and sustainability. The Academy also provides professional and educational resources for researchers across all phases of their careers. Please visit us online atwww.nyas.org.

Read this article:
The New York Academy of Sciences to host programs on the science and law of Lunar Exploration (Wednesday, December 9) and Bioengineering for Space...

Oakland University researchers acquire flow cytometry cell sorter with NSF grant – 2020 – College of Arts and Sciences – News – OU Magazine – News at…

Posted on by

A grant from the National Science Foundation recently helped researchers at Oakland University acquire a flow cytometry cell sorter, a scientific instrument which will allow for hands-on collaborative research in the areas of amphibian biology, plant genomics, and stem cell biology.

A flow cytometry cell sorter is an instrument that is used to perform fluorescent activated cell sorting, which means it can separate or sort small particles, such as cells, chemical compounds, beads, and proteins that are suspended in a stream of fluid, said Dr. Luis Villa-Diaz, an assistant professor in the Biological Sciences and Bioengineering departments at OU.

It does this based on fluorescent signals coming from the particle after it has been stimulated by lasers in the instrument, Villa-Diaz said. If the laser signal makes the particle glow, then a computer will detect that signal and quantify it, and also will direct that particle to a particular container to be collected. Then we can recover the desired particles after theyre sorted and use them for other experiments or purposes.

The flow cytometry cell sorter was obtained using a Major Research Instrumentation (MRI) grant provided by the National Science Foundation. Under the terms of the grant, the NSF covered 70 percent of the cost approximately $544,073 while a collaboration between the Office of the Provost, the College of Arts and Sciences, the Department of Biological Sciences, the Department of Chemistry, the Eye Research Institute, and the Center for Biomedical Research provided the remaining 30 percent ($233,174).

Villa-Diaz will serve as principal investigator on the grant, while Dr. Shailesh Lal, a professor of Biological Sciences and chair of the Bioengineering Department; Dr. Thomas Raffel, an associate professor of Biological Sciences; and Dr. Gerard Madlambayan, an associate professor of Biological Sciences, will serve as co-principal investigators.

I will be using the flow cell sorter to separate different populations of stem cells based on the expression of proteins at their cell membrane, Villa-Diaz said. After sorting and enrichment of the desired cells, we will be able to use and compare the different cell populations using other experimental conditions.

The flow cytometry cell sorter can also be used for a variety of other projects, including the determination of basic biological functions and signaling directed by cell surface proteins in stem cells, the role of endothelial cells on anti-apoptotic pathways, the regulation of pre-mRNA processing in plants, the effects of temperature in amphibian immunology, the development of tubular organs, and basic understanding of DNA repair mechanisms.

The instrument will be available for use by all investigators at OU and investigators from neighboring educational institutions, as well as by users coming from other industries, although there will be a fee involved, Villa-Diaz said. The instrument will also be used for educational purposes in multiple classes, including biology, chemistry and bioengineering.

For more information regarding the use of the instrument, contact Kathie Lesich at lesich@oakland.edu or Suraj Timilsina at surajtimilsina@oakland.edu.

See original here:
Oakland University researchers acquire flow cytometry cell sorter with NSF grant - 2020 - College of Arts and Sciences - News - OU Magazine - News at...

Global Biodecontamination System Market 2020: Expected Development, Share, Demand And Study Of Key Players- Research Predictions 2025 – re:Jerusalem

Posted on by

Global Biodecontamination System Market 2020 by Manufacturers, Regions, Type and Application, Forecast to 2025 describes market introduction, product scope, market overview, and meticulous analysis of the Biodecontamination System market in the forecasted period from 2020 to 2025. The report keenly analyzes significant features in major developing markets. It explains business plans and approaches, consumption propensity, recent changes done by competitors, as well as potential investment breaks. The research report is intended to help readers with a thorough analysis of recent trends, as well as the competitive landscape of the global Biodecontamination System market during the forecast period from 2020 to 2025. The report examines the market in terms of topography, technology, and consumers. The study reveals market dynamics in several geographic segments.

Purpose of This Report:

The purpose of Biodecontamination System report is to offer organized market solutions to market players for smart decision marking. For this reason, the report offers better ideas and solutions in terms of product trends, marketing strategy, future products, new geographical markets, future events, sales strategies, customer actions, or behaviors. The report delivers the value chain analysis together with the traders list and sheds light on the present confronts between consumers and suppliers. It incorporates factual figures, focused scenes, comprehensive division, key patterns, and key proposals.

NOTE: Our report highlights the major issues and hazards that companies might come across due to the unprecedented outbreak of COVID-19.

DOWNLOAD FREE SAMPLE REPORT: https://www.marketsandresearch.biz/sample-request/125234

Key companies profiled in term of company basic information, product introduction, application, specification, production, revenue, price, and gross margin, etc are: STERIS Life Science, Weike Biological Laboratory, TOMI Environmental Solutions, Bioquell, Tailin BioEngineering, Fedegari Group, Howorth Air Technology, JCE Biotechnology, Noxilizer

The most important types of global market products covered in this report are: Chamber Decontamination, Room Decontamination

The most widely used downstream fields of the global market covered in this report are: Pharmaceutical Manufacturing, Bioscience Research, Hospital & Healthcare

This report focuses on volume and value at the global level, regional level, and company level. From a global perspective, this report represents the overall market size by analyzing historical data and future prospects. Regionally, this report focuses on several key regions: North America (United States, Canada and Mexico), Europe (Germany, France, UK, Russia and Italy), Asia-Pacific (China, Japan, Korea, India and Southeast Asia), South America (Brazil, Argentina, etc.), Middle East & Africa (Saudi Arabia, Egypt, Nigeria and South Africa)

The report thoroughly assesses the scope of the growth potential, revenue growth, product range, and pricing factors related to the market. All the expert opinions and the research analysts observations are included in terms of conclusion and observations. The report displays the competitive nature among key manufacturers, with market share, revenue, and sales. The report allows players to achieve the Biodecontamination System market competitive advantage by targeting different customers and target specific products to meet their demands.

ACCESS FULL REPORT: https://www.marketsandresearch.biz/report/125234/global-biodecontamination-system-market-2020-by-manufacturers-regions-type-and-application-forecast-to-2025

Major Market Drivers & Restraints:

Customization of the Report:

This report can be customized to meet the clients requirements. Please connect with our sales team (sales@marketsandresearch.biz), who will ensure that you get a report that suits your needs. You can also get in touch with our executives on +1-201-465-4211 to share your research requirements.

Contact UsMark StoneHead of Business DevelopmentPhone: +1-201-465-4211Email: sales@marketsandresearch.bizWeb: http://www.marketsandresearch.biz

Read more:
Global Biodecontamination System Market 2020: Expected Development, Share, Demand And Study Of Key Players- Research Predictions 2025 - re:Jerusalem

22 IIT Guwahati researchers featured in list of world’s top scientists – Mint

Posted on by

Twenty two faculty members and researchers of Indian Institute of Technology Guwahati were featured in the list of the world's top two per cent scientists created by Stanford University of the USA. The list prepared by experts at Stanford University has names of over 1,00,000 scientists, whose published research manuscripts have accelerated progress in their respective fields and influenced productivity of other researchers as well, a statement issued by IIT Guwahati said.

The institute's Director T G Sitharam and other faculty members were listed and ranked for their research publications citations for the year 2019 and their lifetime contribution to their specific fields of research.

IIT Guwahati faculty members featured in the list are from the Departments of Civil Engineering, Mechanical Engineering, Physics, Chemical Engineering, Biosciences and Bioengineering, Chemistry, Electrical and Electronics. "This recognition of several faculty of the institute in the world's top two per cent of Scientists List has placed it in the global map of science and has brought great pride to the Institute. I congratulate all the 22 scientists and their hard work and commitment to furthering science," Sitharam said. The database report on field specific analysis was prepared by Prof John P A Loannidis of Stanford University and his team and was published in the prestigious journal PLOS Biology, the statement said.

This story has been published from a wire agency feed without modifications to the text.

Subscribe to Mint Newsletters

* Enter a valid email

* Thank you for subscribing to our newsletter.

Read more from the original source:
22 IIT Guwahati researchers featured in list of world's top scientists - Mint

Proteins do a lot more than build muscle. Here’s how we can understand them better. – News@Northeastern

Posted on by

Proteins are the little machines that make cells work. Some keep cells safe from viruses and bacteria, others turn light into food. Proteins carry messages, break down chemicals, copy DNA, and give cells their structure.

Basically, they do everything. Every biological function is performed by proteins, which is why understanding how these molecules work is crucial for many types of research.

But scientists have only recently begun measuring proteins in single cells, and right now, they dont have instruments sensitive enough to measure the trajectories, or lifespans, of proteins that are naturally found within a cell.

Instead, standard practice is to take a large chunk of tissue, grind it up and analyze the average of all proteins in that group of cells, says Nikolai Slavov, assistant professor of bioengineering at Northeastern, whose research focuses on measuring proteins in single cells and chronicling proteins over time. This research is supported by an Allen Distinguished Investigator Award, a Paul G. Allen Frontiers Group advised grant of the Paul G. Allen Family Foundation.

Right now, the standard process for measuring proteins obscures a lot of details. The cells lose their individuality, which is how you can understand a lot about a cells physiology, Slavov says. These current approaches infer the trajectories of single cells and rely on extrapolation.

To make these measurements more accurate, Slavovs lab proposed a method that not only measures proteins in individual cells, but also has the potential to track changes in proteins over time. Slavov says he will use the $1.5 million grant from the Frontiers Group to further develop this advance.

One reason current instruments cant observe protein functions over time is because the measurement process is inherently destructive. To identify the proteins, scientists have to break them down into smaller pieces, either peptides or amino acids, Slavov says.

While Slavovs methods are still destructive, his lab has pioneered a new way to extract information about the cells history in the process.

I like to call it a travelogue of the cell, Slavov says. It can remember and encode information for various proteins in the past, what their turnover was, and what their function was.

Slavovs team created a method of identifying a protein by atomic weight and then following its trajectorya method Slavov plans to further refine with the help of the grant. Heres how it works: Amino acids, the smallest building blocks of a protein, are injected into a cell. These amino acids are composed of atoms that come in various types, called isotopes, which differ by atomic weight because of added neutrons.

The added neutrons dont change the chemical structure of amino acids or the proteins they will create, but they do change the atomic weight. This added weight is used to identify proteins in a cell and measure how they change over time.

This is a simplified example, but lets say on Tuesday we feed the cell amino acids that have a specific weight, then on Wednesday we feed the cell amino acids with a different weight, and on Thursday we feed the cell amino acids with another weight, and so on, says Slavov.

When we eventually do the measurements and break apart the cell, we know which proteins are made on which day because they have a certain weight depending on which amino acids they used, he says.

Identifying when a protein was made is important because it enables scientists to observe how a protein changes over time. Thats one of the biggest questions when it comes to cell differentiation, for example.

Cells differentiateturn into specialized cells such as heart cells, lung cells, brain cells, etc.when they receive information from neighboring cells.

One question we can investigate with this technology is: What are those signals? Slavov says. If we know that information, we can control a cells fate.

Researchers who ask big biomedical questions, such as how the immune system works, or how memories are made, will find these techniques invaluable. But these questions cant be answered with the existing methods, says Slavov. To further advance our research, we need to develop the tools.

For media inquiries, please contact media@northeastern.edu.

See original here:
Proteins do a lot more than build muscle. Here's how we can understand them better. - News@Northeastern

Rail News – CSX names Bostick to its board. For Railroad Career Professionals – Progressive Rail Roading

Posted on by

Rail News Home Railroading People

10/8/2020

Rail News: Railroading People

CSX today announced that Lt. General (Ret.) Thomas Bostick has been appointed to the company's board.

Bostick served in the U.S. Army for 38 years. He served as the chief of engineers and commanding general of the Army Corps of Engineers. After retiring from the military, Bostick was chief operating officer of Intrexon and president of Intrexon Bioengineering.

Bostick is a member of the boards of Perma-Fix Environmental Services Inc., HireVue and Streamside Systems. He's also a member of the National Academy of Engineering.

"We are honored to have Tom join the CSX board of directors," said CSX Chairman John Zillmer in a press release. "Tom's exemplary background of service and leadership will provide the board with an enriching perspective as we guide CSX toward a future of sustainable growth."

Contact Progressive Railroading editorial staff.

Read the original post:
Rail News - CSX names Bostick to its board. For Railroad Career Professionals - Progressive Rail Roading

‘Bioengineers capture the beauty and quirkiness of biology in their art’ – Voxy

Posted on by

The imaginations and technical skills of researchers at the Auckland Bioengineering Institute (ABI) have been unleashed, and are now on show in the Art of Bio Eng exhibition as part of Artweek 2020.

The exhibiton will be on show on the ground floor of the Auckland Public Library 10-18 October and includes 20 works of art.

The works explore the interconnections between art, biology and engineering, and showcases the level and type of research undertaken at the ABI.

Art of Bio Eng includes many intriguing and revealing images: the cell structure of bamboo skewers from a weirdly distorted perspective; the patterns made by EEG waveforms propagated by deeper brain structure; a high-res scan of a bladder in which the tissue resembles the head of a camel.

This is the second time the ABI has held the competition for researchers to show their artistic side. The winning entrants will be announced on October 14 and will be judged by Associate Professor Peter Shand, head of Elam School of Fine Arts, Kate Harsant (Elam alumna and ABI executive assistant) and Arron Hynds, Director of Research Development at Hynds Smarter Water.

Associate Professor Peng Du is also on the judging panel. He organised the first Art of Bio Eng in 2015, and he notes that this years competition has attracted entrants from a wider selection of subject areas.

"It really shows that the field is growing and is more interconnected than ever before." The competition is a way to change the misperception that engineers, or STEM subjects are boring and "all about theories and equations", he says.

"As a biomedical engineer, I study the same natural aspects of the living body that are celebrated by athletes and artists throughout the ages. With advances in technologies, we are now able to visualise a world that would otherwise be closed off to our imaginations and investigations." Reuben Keeling, senior communications adviser at the ABI, helped organise the event this year and was both surprised and thrilled by the number of entries. Art of Bio Eng is a unique way to show off what the ABI does, he says.

"I dont think many people know about the Institute or the life-changing research ABI researchers are doing, so we challenged our researchers to take a different perspective on their projects, to create something artistic and get peoples attention. There are some really stunning pieces in this collection - who knew bioengineers could be so creative?"

You can view all the entrants and vote for your favourite in the People Choice on the 2020 Art of Bio Eng website.

More here:
'Bioengineers capture the beauty and quirkiness of biology in their art' - Voxy

Regulation of Animal Subjects Research – The Regulatory Review

Posted on by

Scholars discuss whether the Animal Welfare Act achieves its aim of protecting animal research subjects.

Biomedical and behavioral researchers use animals as research subjects to improve human health. For example, physicians used cats and dogs to develop the medical technology that would eventually make open heart surgery possible. Today, scientists developing coronavirus vaccines first tested on animals before moving to human subjects.

In the United States, the Animal Welfare Act (AWA) is the primary regulatory instrument to protect animal research subjects. The AWA protects warm-blooded animals used in research, commercial sale, public exhibition, or commercial transport. The law contains standards for the treatment of animals in research and requires institutional oversight of all animal subjects research. The U.S. Department of Agriculture enforces the AWA through routine inspections of research facilities.

Scholars differ on whether the AWA does enough to protect animal welfare. Some organizations oppose using any form of animal research, but others maintain that animal research is necessary for the continued improvement of medical techniques and treatments.

This weeks Saturday Seminar focuses on the AWA and protections for the use of animals as test subjects in scientific research.

Here is the original post:
Regulation of Animal Subjects Research - The Regulatory Review

Report of the president: Appointments and promotions | Stanford News – Stanford University News

Posted on by

APPOINTMENTS WITHOUT LIMIT OF TIME:

DeSimone, Joseph, Professor of Radiology and of Chemical Engineering, effective September 1, 2020

Hernandez-Boussard, Tina, Associate Professor of Medicine, and by courtesy, of Surgery, effective November 1, 2020

Rose, Sherri, Associate Professor of Medicine, effective August 1, 2020.

Setsompop, Kawin, Associate Professor of Radiology, effective November 1, 2020

PROMOTIONS WITHOUT LIMIT OF TIME:

Bauer, Andrew, Associate Professor of Anthropology, effective September 1, 2020

Collins, Steven, Associate Professor of Mechanical Engineering, effective November 1, 2020

Dixon, Scott, Associate Professor of Biology, effective January 1, 2021

Feng, Liang, Associate Professor of Molecular and Cellular Physiology, effective October 1, 2020

Goldbogen, Jeremy, Associate Professor of Biology, effective January 1, 2021

Gweon, Hyowon, Associate Professor of Psychology, effective September 1, 2020

Huh, June, Professor of Mathematics, effective September 1, 2020

Pasa, Sergiu, Associate Professor of Psychiatry and Behavioral Sciences, effective August 1, 2020

Rivas-Davila, Juan, Associate Professor of Electrical Engineering, effective September 1, 2020

Seetah, Krish, Associate Professor of Anthropology, effective August 1, 2020

Simard, Julia, Associate Professor of Epidemiology and Population Health, and by courtesy, of Medicine, effective January 1, 2021

Stanford, Douglas, Associate Professor of Physics, effective September 1, 2020

Yan Xia, Associate Professor of Chemistry, effective September 1, 2020

PROMOTION FOR A CONTINUING TERM:

Srivastava, Sakti, Professor (Teaching) of Surgery, effective October 1, 2020

OTHER APPOINTMENTS:

Achour, Sara, Assistant Professor (subject to Ph.D.) of Computer Science, for the period September 1, 2020 through August 31, 2024

Allende Santa Cruz, Claudia, Assistant Professor of Economics in the Graduate School of Business, for the period July 1, 2021 through June 30, 2025

Banik, Steven, Assistant Professor of Chemistry, for the period September 1, 2021 through August 31, 2025

Bouland, Adam, Assistant Professor of Computer Science, for the period September 1, 2020 through August 31, 2024

Chaudhari, Akshay, Assistant Professor (Research) of Radiology, for the period October 1, 2020 through September 30, 2024, coterminous with continued salary and research funding from sponsored projects

Clark, Susan, Assistant Professor of Physics, for the period September 1, 2021 through August 31, 2025

Fletcher, Brian, Associate Professor (Teaching) of Law, for the period September 1, 2020 through August 31, 2023

Geldsetzer, Pascal, Assistant Professor of Medicine, for the period November 1, 2020 through October 31, 2024

Kasowski, Maya, Assistant Professor of Medicine and of Pathology, and by courtesy, of Genetics, for the period July 1, 2020 through June 20, 2024

Kozleski, Elizabeth, Professor (Research) of Education, for the period August 31, 2020 through August 30, 2025, coterminous with continued salary and research funding from sponsored projects

Liu, Fang, Assistant Professor of Chemistry, for the period September 1, 2020 through August 31, 2024

Mason, Daniel, Assistant Professor of Psychiatry and Behavioral Sciences, for the period October 1, 2020 through September 30, 2024

Sharaf, Naima, Assistant Professor of Biology, for the period September 1, 2021 through August 31, 2025

Trivedi, Mudit, Assistant Professor (subject to Ph.D.) of Anthropology, for the period July 1, 2021 through June 30, 2025

OTHER PROMOTIONS:

Blanchet, Jose, Professor of Management Science and Engineering, effective September 1, 2020

Gipper, Brandon, Associate Professor of Accounting in the Graduate School of Business, for the period July 1, 2020 through June 30, 2023

Hbert, Benjamin, Associate Professor of Finance in the Graduate School of Business, for the period August 1, 2020 through July 31, 2023

Heilshorn, Sarah, Professor of Materials Science and Engineering, and by courtesy, of Chemical Engineering and of Bioengineering, effective August 1, 2020

Spakowitz, Andrew, Professor of Chemical Engineering and of Materials Science and Engineering, effective September 1, 2020

Yang, Peter, Professor of Orthopaedic Surgery, effective October 1, 2020

OTHER REAPPOINTMENTS:

Auclert, Adrien, Assistant Professor of Economics, for the period July 1, 2023 through June 30, 2024

Bacchetta, Rosa, Associate Professor (Research) of Pediatrics, for the period August 1, 2020 through April 30, 2025, coterminous with continued salary and research funding from sponsored projects

Baiocchi, Michael, Assistant Professor of Epidemiology and Population Health and, by courtesy, of Statistics and of Medicine, for the period September 1, 2021 through August, 2022

Battiato, Ilenia, Assistant Professor of Earth System Science, for the period September 1, 2020 through August 31, 2023

Bernert, Rebecca, Assistant Professor of Psychiatry and Behavioral Sciences, for the period October 1, 2021 through September 30, 2022

Bocolo, Luigi, Assistant Professor of Economics, for the period August 1, 2022 through July 31, 2023

Boettiger, Alistair, Assistant Professor of Developmental Biology, for the period September 1, 2020 through August 31, 2023

Brandman, Onn, Assistant Professor of Biochemistry, for the period September 1, 2020 through November 30, 2020

Chan, David, Assistant Professor of Medicine, for the period November 1, 2022 through October 31, 2023

Chaudhuri, Ovijit, Assistant Professor of Mechanical Engineering, for the period August 1, 2020 through September 30, 2020

Clement, Julien, Assistant Professor of Organizational Behavior in the Graduate School of Business, for the period July 17, 2022 through July 16, 2023

Cuesta Rodriguez, Jos, Assistant Professor of Economics, for the period July 1, 2024 through June 30, 2026

Dubra, Alfredo, Associate Professor of Ophthalmology, for the period September 1, 2020 through August 31, 2021

Duncan, Laramie, Assistant Professor of Psychiatry and Behavioral Sciences, for the period September 1, 2022 through August 31, 2023

Dunn, Laura, Professor of Psychiatry and Behavioral Sciences, for the period September 1, 2020 through November 30, 2020

Dylan, Dodd, Assistant Professor of Pathology and of Microbiology and Immunology, for the period August 16, 2022 through August 15, 2023

Ellsworth, William, Professor (Research) of Geophysics, for the period October 4, 2020 through October 3, 2025, coterminous with continued salary and research funding from sponsored projects

Feldman, Brian, Assistant Professor of Physics, for the period September 1, 2021 through December 31, 2021

Fetter, Dan, Assistant Professor of Economics, for the period July 1, 2024 through June 30, 2025

Frock, Richard, Assistant Professor of Radiation Oncology, for the period January 1, 2022 through December 31, 2022

Fung, Lawrence, Assistant Professor of Psychiatry and Behavioral Sciences, for the period July 1, 2023 through June 30, 2024

Gao, Xiaojing, Assistant Professor of Chemical Engineering, for the period April 1, 2024 through March 31, 2025

Garcia, Antero, Assistant Professor of Education, for the period January 1, 2021 through December 31, 2023

Gorle, Catherine, Assistant Professor of Civil and Environmental Engineering, for the period July 1, 2020 through June 30, 2024

Grillet, Nicolas, Assistant Professor of Otolaryngology Head and Neck Surgery, for the period April 1, 2023 through March 31, 2024

Gross, Eric, Assistant Professor of Anesthesiology, Perioperative and Pain Medicine, for the period September 1, 2021 through August 31, 2022

Gu, Xun, Assistant Professor of Mechanical Engineering and, by courtesy, of Materials Science and Engineering, for the period June 1, 2022 through May 31, 2023

Heaney, Catherine, Associate Professor (Teaching) of Psychology and of Medicine, for the period July 1, 2020 through June 30, 2025

Hebert, Benjamin, Associate Professor of Finance in the Graduate School of Business, for the period August 1, 2023 through July 31, 2024

Hoffman, Mark, Assistant Professor of Sociology, for the period October 16, 2023 through October 15, 2024

Honigsberg, Colleen, Associate Professor of Law, for the period June 1, 2023 through May 31, 2025

Hu, Yang, Assistant Professor of Ophthalmology, for the period December 1, 2020 through November 30, 2021

Huang, Possu, Assistant Professor of Bioengineering, for the period October 1, 2020 through August 31, 2022

Huang, Ting Ting, Associate Professor (Research) of Neurology and Neurological Sciences, for the period November 1, 2020 through October 31, 2021, coterminous with continued salary and research funding from sponsored projects

Iyer, Usha, Assistant Professor of Art and Art History, for the period June 1, 2023 through May 31, 2024

Jagannathan, Prassana, Assistant Professor of Medicine and of Microbiology and Immunology, for the period January 1, 2021 through December 31, 2023

Jaiswal, Siddhartha, Assistant Professor of Pathology, for the period November 1, 2021 through October 31, 2022

Kaltschmidt, Julia, Associate Professor of Neurosurgery, for the period April 1, 2021 through March 31, 2022

Kantor, Roanne, Assistant Professor of English, for the period July 1, 2022 through June 30, 2023

Kasowski, Maya, Assistant Professor of Medicine, and by courtesy, of Genetics, for the period July 1, 2024 through June 30, 2025

Keca, Srdan, Assistant Professor of Art and Art History, for the period September 1, 2023 through August 31, 2024

Konermann, Silvana, Assistant Professor of Biochemistry, for the period October 1, 2023 through September 30, 2024

Konings, Alexandra, Assistant Professor of Earth System Science, for the period September 1, 2020 through August 31, 2023

Kronengold, Charles, Assistant Professor of Music, for the period January 1, 2021 through June 30, 2022

Kundaje, Anshul, Assistant Professor of Genetics and of Computer Science, for the period December 1, 2020 through November 30. 2022

Kwon, Marci, Assistant Professor of Art and Art History, for the period August 1, 2023 through July 31, 2024

Larson, Bradley, Assistant Professor of Economics, for the period August 1, 2023 through July 30, 2024

Linderman, Scott, Assistant Professor of Statistics, for the period June 1, 2023 through May 31, 2025

Long, Jonathan, Assistant Professor of Pathology, for the period January 1, 2023 through December 1, 2023

Mai, Danielle, Assistant Professor of Chemical Engineering, for the period January 1, 2024 through December 31, 2024

Mannix, Andrew, Assistant Professor of Materials Science and Engineering, for the period August 1, 2024 through July 31, 2025

Martinez-Martin, Nicole, Assistant Professor (Research) of Pediatrics, for the period December 1, 2023 through November 30, 2024, coterminous with continued salary and research funding from sponsored projects

Morten, Melanie, Assistant Professor of Economics, for the period July 1, 2021 through June 30, 2022

Mross, Michaela, Assistant Professor of Religious Studies, for the period September 1, 2023 through August 31, 2024

Newman, Aaron, Assistant Professor of Biomedical Data Science, for the period August 1, 2021 through July 31, 2022

Palacios, Julia, Assistant Professor of Statistics and of Biomedical Data Science, for the period September 1, 2021 through August 31, 2024

Read more from the original source:
Report of the president: Appointments and promotions | Stanford News - Stanford University News

Rigaku to Lead Development of New Soft X-ray Phase-Based Microscope for Biomedical Applications – PR Web

Posted on by

The goal of the new project is to deliver an intensity-modulated phase-based soft X-ray microscopy system for non-destructive synchrotron-quality imaging of biological samples.

THE WOODLANDS, Texas (PRWEB) October 06, 2020

Rigaku Corporation, a global leader in X-ray analytical instrumentation, will lead a consortium of scientific and academic research institutions in the development a new soft X-ray phase-based microscope for biomedical applications. Rigaku, University College London, Creatv MicroTech, Argonne National Laboratory and Sloan Kettering Institute for Cancer Research have been granted funds by the National Institute of Biomedical Imaging and Bioengineering (NIBIB) to develop an intensity-modulated phase-based soft X-ray microscope.

Microscopy is a cornerstone of both biomedical research and clinical practice. There are, however, imaging needs that are not satisfied by light, electron or X-ray methods. While optical light is satisfactory for thin tissue slices, it is not suitable for obtaining quality 3D images of thick tissue. X-rays can penetrate thick tissue, but X-ray microscope imaging systems that are available commercially are not optimal for soft tissue imaging. Additionally, the resolution of current micro-computed tomography (CT) machines is insufficient for cancer grading and scoring.

The goal of the new project is to deliver an intensity-modulated phase-based soft X-ray microscopy system for non-destructive synchrotron-quality imaging of biological samples. The system will provide 3D, quantitative and multimodal images with shorter acquisition times than from currently available systems, and resolution comparable to that of visible light microscopes, rendering high-contrast images of cell composition. In the last year of the project, the microscope will be installed at Memorial Sloan Kettering Cancer Center and tested on a range of relevant samples in order to evaluate its potential both as a clinical and as a research tool.

About Rigaku

Since its inception in Japan in 1951, Rigaku has been at the forefront of analytical and industrial instrumentation technology. Rigaku and its subsidiaries form a global group focused on general-purpose analytical instrumentation and the life sciences. With hundreds of major innovations to their credit, Rigaku companies are world leaders in X-ray spectrometry, diffraction, and optics, as well as small molecule and protein crystallography and semiconductor metrology. Today, Rigaku employs over 1,400 people in the manufacturing and support of its analytical equipment, which is used in more than 90 countries around the world supporting research, development, and quality assurance activities. Throughout the world, Rigaku continuously promotes partnerships, dialog, and innovation within the global scientific and industrial communities.

For further information, contact:

Joseph D. Ferrara, Ph.D.,CSO, Rigaku Americas Corporationtel: +1 281-362-2300 Joseph.Ferrara@rigaku.com

Share article on social media or email:

See original here:
Rigaku to Lead Development of New Soft X-ray Phase-Based Microscope for Biomedical Applications - PR Web

NIH RADx initiative advances six new COVID-19 testing technologies – National Institutes of Health

Posted on by

News Release

Tuesday, October 6, 2020

The National Institutes of Health, working in collaboration with the Biomedical Advanced Research and Development Authority (BARDA), today announced a third round of contract awards for scale-up and manufacturing of new COVID-19 testing technologies. The six new Rapid Acceleration of Diagnostics (RADx) initiative contracts total $98.35 million for point-of-care and other novel test approaches that provide new modes of sample collection, processing and return of results. Innovations in these new technologies include integration with smart devices, mobile-lab processing that can be deployed to COVID-19 hot spots, and test results available within minutes.

These awards are part of the RADx Tech program, focused on rapidly advancing early testing technologies. RADx Tech and the RADx Advanced Technology Platforms (RADx-ATP) the latter for late-stage scale-up projects are now supporting a combined portfolio of 22 companies for a total of $476.4 million in manufacturing expansion contracts. These six additional technologies are expected to add as many as 500,000 tests per day to the U.S. capacity by the end of 2020 and 1 million tests per day by early 2021. Combined with previous contractsannounced in July and September, RADx Tech and RADx-ATP contracts are expected to increase test capacity by 2.7 million tests per day by the end of 2020.

Since launching in April, the NIH RADx initiative has moved swiftly to facilitate critical expansion of early and late-stage testing technologies as well as research to remove barriers to testing for underserved and vulnerable populations, said NIH Director Francis S. Collins, M.D., Ph.D. Each of the technologies emerging from the RADx initiative will play a critical role in extending accessibility to testing in diverse settings.

The latest group of testing technologies have been optimized and assessed within the NIH RADx Tech development pipeline and have met the rigorous criteria for advancement. Factors such as speed, accuracy, cost and accessibility are key considerations for RADx support. The RADx initiative provides financial support and expertise to help companies reach milestones for U.S. Food and Drug Administration authorization, scale-up and commercialization.

The current round of awards support five technologies that can be delivered to the point of care and a powerful laboratorytest, said Bruce J. Tromberg, Ph.D., director of the National Institute of Biomedical Imaging and Bioengineering (NIBIB) and lead for RADx Tech, one of four programs of the NIH RADx initiative. The technologies include an antigen test that provides results in 15 minutes, a viral RNA test deployed in mobile vans that can travel to COVID hotspots and tests that require only saliva, nasal swabs or blood from a finger prick.

BARDA, part of the Office of the Assistant Secretary for Preparedness and Response within the U.S. Department of Health and Human Services, provided the funding for these RADx Tech contracts from emergency supplemental appropriations to the Public Health and Social Services Emergency Fund.

BARDA has contributed substantially to the nations COVID testing capacity with development support of 30 SARS-COV-2 diagnostic tests since March, 15 of which have achieved FDA emergency use authorization (EUA). Five of the 30 tests can distinguish between influenza and SARS-COV-2, the virus that causes COVID-19, from the same sample, and two of those have achieved EUA. To date, BARDAs industry partners have shipped more than 45 million tests to healthcare providers across the country.

Through the RADx initiative, we are expanding on our long-standing partnership with NIH to bring essential technology to the American people in the fight against COVID-19, said BARDA Acting Director Gary L. Disbrow, Ph.D.Our staff at BARDA is lending our expertise and experience in advanced development, manufacturing and scale up to help make as many accurate, fast tests available as we can as quickly as possible.

The following companies have achieved key RADx Tech milestones and will receive support for manufacturing and scale up:

Ellume USA LLC, Valencia, California

Two unique test cartridges contain a single-use, digital fluorescent immunoassay antigen test that returns accurate results in 15 minutes or less.One cartridge testing nasal swabs can be read out on two platforms by healthcare professionals, at the point of care or in laboratory settings for higher throughput. A second cartridge is being developed for home use with a self-administered nasal swab.

Luminostics, Inc., Milpitas, California

A rapid, smartphone-readout, antigen immunoassay that uses glow-in-the-dark nanomaterials to sensitively and specifically detect SARS-CoV-2 from shallow nasal swabs in 30 minutes or less, first for point-of-care use and later for home use.

Quanterix, Billerica, Massachusetts

A laboratory antigen test with ultra-sensitive single-molecule immunoassay technology to enable detection from a variety of sample types including nasopharyngeal, saliva or self-acquired blood from a finger prick. Sample collection, transport, and processing will occur within 24-48 hours using existing sample collection logistics infrastructure through a network of centralized labs.

Flambeau Diagnostics, Madison, Wisconsin

A lab module that can be deployed in a mobile van to screen asymptomatic individuals to detect SARS-CoV-2at low viral levelsin saliva samples, returning results in as little as one hour. The system can serve employers, schools and underserved populations. It uses newextractiontechnology to purify and concentrate viral RNA reliably and quickly.

Ubiquitome, Auckland, New Zealand

A battery-operated, mobile RT-PCR device that detects viral RNA with high accuracy in 40 minutes and reports results via its proprietary iPhone app. It offers high throughput and could be much lower cost than lab-based RT-PCR tests. The device is targeted for use in rural and metropolitan hospitals and mobile labs.

Visby Medical, San Jose, California

A palm-sized, single-use RT-PCR device that detects viral RNA with highly accurate results at the point of care in 30 minutes. The device was designed to be used by a person with minimal skills. This novel, versatile technology platform can also be adapted to provide simple, rapid tests for other diseases such as chlamydia, gonorrhea, and influenza.

About the Rapid Acceleration of Diagnostics (RADx SM) initiative: The RADx initiative was launched on April 29, 2020, to speed innovation in the development, commercialization, and implementation of technologies for COVID-19 testing. The initiative has four programs: RADx Tech, RADx Advanced Technology Platforms, RADx Underserved Populations and RADx Radical. It leverages the existing NIH Point-of-Care Technology Research Network. The RADx initiative partners with federal agencies, including the Office of the Assistant Secretary of Health, Department of Defense, the Biomedical Advanced Research and Development Authority, and U.S. Food and Drug Administration. Learn more about the RADx initiative and its programs:https://www.nih.gov/radx.

About HHS, ASPR, and BARDA: HHS works to enhance and protect the health and well-being of all Americans, providing for effective health and human services and fostering advances in medicine, public health, and social services. The mission of ASPR is to save lives and protect Americans from 21st century health security threats. Within ASPR, BARDA invests in the innovation, advanced research and development, acquisition, and manufacturing of medical countermeasures vaccines, drugs, therapeutics, diagnostic tools, and non-pharmaceutical products needed to combat health security threats. To date, 55 BARDA-supported products have achieved FDA approval, licensure or clearance. For more on BARDAs portfolio for COVID-19 diagnostics, vaccines and treatments and about partnering with BARDA, visit medicalcountermeasures.gov. To learn more about federal support for the all-of-America COVID-19 response, visit coronavirus.gov.

About the National Institute of Biomedical Imaging and Bioengineering (NIBIB):NIBIBs mission is to improve health by leading the development and accelerating the application of biomedical technologies. The Institute is committed to integrating the physical and engineering sciences with the life sciences to advance basic research and medical care. NIBIB supports emerging technology research and development within its internal laboratories and through grants, collaborations, and training. More information is available at the NIBIB website:https://www.nibib.nih.gov.

About the National Institutes of Health (NIH):NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit http://www.nih.gov.

NIHTurning Discovery Into Health

###

Continue reading here:
NIH RADx initiative advances six new COVID-19 testing technologies - National Institutes of Health

Virtual Rehabilitation System Market Size, Sales, Profit Margin, Key Competencies, Restraints Throughout The Forecasted Period 2020-2026|VRHealth,…

Posted on by

LOS ANGELES, United States:The report titledGlobal Virtual Rehabilitation System Marketis one of the most comprehensive and important additions to QY Researchs archive of market research studies. It offers detailed research and analysis of key aspects of the global Virtual Rehabilitation System market. The market analysts authoring this report have provided in-depth information on leading growth drivers, restraints, challenges, trends, and opportunities to offer a complete analysis of the global Virtual Rehabilitation System market. Market participants can use the analysis on market dynamics to plan effective growth strategies and prepare for future challenges beforehand. Each trend of the global Virtual Rehabilitation System market is carefully analyzed and researched about by the market analysts.The market analysts and researchers have done extensive analysis of the global Virtual Rehabilitation System market with the help of research methodologies such as PESTLE and Porters Five Forces analysis. They have provided accurate and reliable market data and useful recommendations with an aim to help the players gain an insight into the overall present and future market scenario. The Virtual Rehabilitation System report comprises in-depth study of the potential segments including product type, application, and end user and their contribution to the overall market size.

Get Full PDF Sample Copy of Report: (Including Full TOC, List of Tables & Figures, Chart)https://www.qyresearch.com/sample-form/form/1664008/global-virtual-rehabilitation-system-market

In addition, market revenues based on region and country are provided in the Virtual Rehabilitation System report. The authors of the report have also shed light on the common business tactics adopted by players. The leading players of the global Virtual Rehabilitation System market and their complete profiles are included in the report. Besides that, investment opportunities, recommendations, and trends that are trending at present in the global Virtual Rehabilitation System market are mapped by the report. With the help of this report, the key players of the global Virtual Rehabilitation System market will be able to make sound decisions and plan their strategies accordingly to stay ahead of the curve.

Competitive landscape is a critical aspect every key player needs to be familiar with. The report throws light on the competitive scenario of the global Virtual Rehabilitation System market to know the competition at both the domestic and global levels. Market experts have also offered the outline of every leading player of the global Virtual Rehabilitation System market, considering the key aspects such as areas of operation, production, and product portfolio. Additionally, companies in the report are studied based on the key factors such as company size, market share, market growth, revenue, production volume, and profits.

Key Players Mentioned in the Global Virtual Rehabilitation System Market Research Report: :, VRHealth, Motek Medical, Virtual Rehab, ACP, BTS Bioengineering, GestureTek Health, CoRehab, CSE Entertainment, Doctor Kinetic, LiteGait, Meden-Inmed, Saebo, Tyromotion

Virtual Rehabilitation System Market Types: , Cloud-based, On Premise

Virtual Rehabilitation System Market Applications:, Hospital, Clinic, Other

The Virtual Rehabilitation System Market report has been segregated based on distinct categories, such as product type, application, end user, and region. Each and every segment is evaluated on the basis of CAGR, share, and growth potential. In the regional analysis, the report highlights the prospective region, which is estimated to generate opportunities in the global Virtual Rehabilitation System market in the forthcoming years. This segmental analysis will surely turn out to be a useful tool for the readers, stakeholders, and market participants to get a complete picture of the global Virtual Rehabilitation System market and its potential to grow in the years to come.

Key questions answered in the report:

Request for customization in Report:https://www.qyresearch.com/customize-request/form/1664008/global-virtual-rehabilitation-system-market

Table of Contents:

1 Market Overview of Virtual Rehabilitation System1.1 Virtual Rehabilitation System Market Overview1.1.1 Virtual Rehabilitation System Product Scope1.1.2 Market Status and Outlook1.2 Global Virtual Rehabilitation System Market Size Overview by Region 2015 VS 2020 VS 20261.3 Global Virtual Rehabilitation System Market Size by Region (2015-2026)1.4 Global Virtual Rehabilitation System Historic Market Size by Region (2015-2020)1.5 Global Virtual Rehabilitation System Market Size Forecast by Region (2021-2026)1.6 Key Regions Virtual Rehabilitation System Market Size YoY Growth (2015-2026)1.6.1 North America Virtual Rehabilitation System Market Size YoY Growth (2015-2026)1.6.2 Europe Virtual Rehabilitation System Market Size YoY Growth (2015-2026)1.6.3 China Virtual Rehabilitation System Market Size YoY Growth (2015-2026)1.6.4 Rest of Asia Pacific Virtual Rehabilitation System Market Size YoY Growth (2015-2026)1.6.5 Latin America Virtual Rehabilitation System Market Size YoY Growth (2015-2026)1.6.6 Middle East & Africa Virtual Rehabilitation System Market Size YoY Growth (2015-2026)1.7 Coronavirus Disease 2019 (Covid-19): Virtual Rehabilitation System Industry Impact1.7.1 How the Covid-19 is Affecting the Virtual Rehabilitation System Industry

1.7.1.1 Virtual Rehabilitation System Business Impact Assessment Covid-19

1.7.1.2 Supply Chain Challenges

1.7.1.3 COVID-19s Impact On Crude Oil and Refined Products1.7.2 Market Trends and Virtual Rehabilitation System Potential Opportunities in the COVID-19 Landscape1.7.3 Measures / Proposal against Covid-19

1.7.3.1 Government Measures to Combat Covid-19 Impact

1.7.3.2 Proposal for Virtual Rehabilitation System Players to Combat Covid-19 Impact 2 Virtual Rehabilitation System Market Overview by Type2.1 Global Virtual Rehabilitation System Market Size by Type: 2015 VS 2020 VS 20262.2 Global Virtual Rehabilitation System Historic Market Size by Type (2015-2020)2.3 Global Virtual Rehabilitation System Forecasted Market Size by Type (2021-2026)2.4 Cloud-based2.5 On Premise 3 Virtual Rehabilitation System Market Overview by Type3.1 Global Virtual Rehabilitation System Market Size by Application: 2015 VS 2020 VS 20263.2 Global Virtual Rehabilitation System Historic Market Size by Application (2015-2020)3.3 Global Virtual Rehabilitation System Forecasted Market Size by Application (2021-2026)3.4 Hospital3.5 Clinic3.6 Other 4 Global Virtual Rehabilitation System Competition Analysis by Players4.1 Global Virtual Rehabilitation System Market Size (Million US$) by Players (2015-2020)4.2 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Virtual Rehabilitation System as of 2019)4.3 Date of Key Manufacturers Enter into Virtual Rehabilitation System Market4.4 Global Top Players Virtual Rehabilitation System Headquarters and Area Served4.5 Key Players Virtual Rehabilitation System Product Solution and Service4.6 Competitive Status4.6.1 Virtual Rehabilitation System Market Concentration Rate4.6.2 Mergers & Acquisitions, Expansion Plans 5 Company (Top Players) Profiles and Key Data5.1 VRHealth5.1.1 VRHealth Profile5.1.2 VRHealth Main Business and Companys Total Revenue5.1.3 VRHealth Products, Services and Solutions5.1.4 VRHealth Revenue (US$ Million) (2015-2020)5.1.5 VRHealth Recent Developments5.2 Motek Medical5.2.1 Motek Medical Profile5.2.2 Motek Medical Main Business and Companys Total Revenue5.2.3 Motek Medical Products, Services and Solutions5.2.4 Motek Medical Revenue (US$ Million) (2015-2020)5.2.5 Motek Medical Recent Developments5.3 Virtual Rehab5.5.1 Virtual Rehab Profile5.3.2 Virtual Rehab Main Business and Companys Total Revenue5.3.3 Virtual Rehab Products, Services and Solutions5.3.4 Virtual Rehab Revenue (US$ Million) (2015-2020)5.3.5 ACP Recent Developments5.4 ACP5.4.1 ACP Profile5.4.2 ACP Main Business and Companys Total Revenue5.4.3 ACP Products, Services and Solutions5.4.4 ACP Revenue (US$ Million) (2015-2020)5.4.5 ACP Recent Developments5.5 BTS Bioengineering5.5.1 BTS Bioengineering Profile5.5.2 BTS Bioengineering Main Business and Companys Total Revenue5.5.3 BTS Bioengineering Products, Services and Solutions5.5.4 BTS Bioengineering Revenue (US$ Million) (2015-2020)5.5.5 BTS Bioengineering Recent Developments5.6 GestureTek Health5.6.1 GestureTek Health Profile5.6.2 GestureTek Health Main Business and Companys Total Revenue5.6.3 GestureTek Health Products, Services and Solutions5.6.4 GestureTek Health Revenue (US$ Million) (2015-2020)5.6.5 GestureTek Health Recent Developments5.7 CoRehab5.7.1 CoRehab Profile5.7.2 CoRehab Main Business and Companys Total Revenue5.7.3 CoRehab Products, Services and Solutions5.7.4 CoRehab Revenue (US$ Million) (2015-2020)5.7.5 CoRehab Recent Developments5.8 CSE Entertainment5.8.1 CSE Entertainment Profile5.8.2 CSE Entertainment Main Business and Companys Total Revenue5.8.3 CSE Entertainment Products, Services and Solutions5.8.4 CSE Entertainment Revenue (US$ Million) (2015-2020)5.8.5 CSE Entertainment Recent Developments5.9 Doctor Kinetic5.9.1 Doctor Kinetic Profile5.9.2 Doctor Kinetic Main Business and Companys Total Revenue5.9.3 Doctor Kinetic Products, Services and Solutions5.9.4 Doctor Kinetic Revenue (US$ Million) (2015-2020)5.9.5 Doctor Kinetic Recent Developments5.10 LiteGait5.10.1 LiteGait Profile5.10.2 LiteGait Main Business and Companys Total Revenue5.10.3 LiteGait Products, Services and Solutions5.10.4 LiteGait Revenue (US$ Million) (2015-2020)5.10.5 LiteGait Recent Developments5.11 Meden-Inmed5.11.1 Meden-Inmed Profile5.11.2 Meden-Inmed Main Business and Companys Total Revenue5.11.3 Meden-Inmed Products, Services and Solutions5.11.4 Meden-Inmed Revenue (US$ Million) (2015-2020)5.11.5 Meden-Inmed Recent Developments5.12 Saebo5.12.1 Saebo Profile5.12.2 Saebo Main Business and Companys Total Revenue5.12.3 Saebo Products, Services and Solutions5.12.4 Saebo Revenue (US$ Million) (2015-2020)5.12.5 Saebo Recent Developments5.13 Tyromotion5.13.1 Tyromotion Profile5.13.2 Tyromotion Main Business and Companys Total Revenue5.13.3 Tyromotion Products, Services and Solutions5.13.4 Tyromotion Revenue (US$ Million) (2015-2020)5.13.5 Tyromotion Recent Developments 6 North America Virtual Rehabilitation System by Players and by Application6.1 North America Virtual Rehabilitation System Market Size and Market Share by Players (2015-2020)6.2 North America Virtual Rehabilitation System Market Size by Application (2015-2020) 7 Europe Virtual Rehabilitation System by Players and by Application7.1 Europe Virtual Rehabilitation System Market Size and Market Share by Players (2015-2020)7.2 Europe Virtual Rehabilitation System Market Size by Application (2015-2020) 8 China Virtual Rehabilitation System by Players and by Application8.1 China Virtual Rehabilitation System Market Size and Market Share by Players (2015-2020)8.2 China Virtual Rehabilitation System Market Size by Application (2015-2020) 9 Rest of Asia Pacific Virtual Rehabilitation System by Players and by Application9.1 Rest of Asia Pacific Virtual Rehabilitation System Market Size and Market Share by Players (2015-2020)9.2 Rest of Asia Pacific Virtual Rehabilitation System Market Size by Application (2015-2020) 10 Latin America Virtual Rehabilitation System by Players and by Application10.1 Latin America Virtual Rehabilitation System Market Size and Market Share by Players (2015-2020)10.2 Latin America Virtual Rehabilitation System Market Size by Application (2015-2020) 11 Middle East & Africa Virtual Rehabilitation System by Players and by Application11.1 Middle East & Africa Virtual Rehabilitation System Market Size and Market Share by Players (2015-2020)11.2 Middle East & Africa Virtual Rehabilitation System Market Size by Application (2015-2020) 12 Virtual Rehabilitation System Market Dynamics12.1 Industry Trends12.2 Market Drivers12.3 Market Challenges12.4 Porters Five Forces Analysis 13 Research Finding /Conclusion 14 Methodology and Data Source 14.1 Methodology/Research Approach14.1.1 Research Programs/Design14.1.2 Market Size Estimation14.1.3 Market Breakdown and Data Triangulation14.2 Data Source14.2.1 Secondary Sources14.2.2 Primary Sources14.3 Disclaimer14.4 Author List

About Us:

QY Research established in 2007, focus on custom research, management consulting, IPO consulting, industry chain research, data base and seminar services. The company owned a large basic data base (such as National Bureau of statistics database, Customs import and export database, Industry Association Database etc), experts resources (included energy automotive chemical medical ICT consumer goods etc.

View original post here:
Virtual Rehabilitation System Market Size, Sales, Profit Margin, Key Competencies, Restraints Throughout The Forecasted Period 2020-2026|VRHealth,...

AI tool could predict how drugs will react in the body – Futurity: Research News

Posted on by

Share this Article

You are free to share this article under the Attribution 4.0 International license.

A new deep learning-based tool called Metabolic Translator may soon give researchers a better handle on how drugs in development will perform in the human body.

When you take a medication, you want to know precisely what it does. Pharmaceutical companies go through extensive testing to ensure that you do.

Metabolic Translator, a computational tool that predicts metabolites, the products of interactions between small molecules like drugs and enzymes could help improve the process.

The new tool takes advantage of deep-learning methods and the availability of massive reaction datasets to give developers a broad picture of what a drug will do. The method is unconstrained by rules that companies use to determine metabolic reactions, opening a path to new discoveries.

When youre trying to determine if a compound is a potential drug, you have to check for toxicity, says Lydia Kavraki, a professor of computer science, a professor of bioengineering, mechanical engineering, and electrical and computer engineering, and director of Rices Ken Kennedy Institute, as well ascoauthor of the new paper in Chemical Science.

You want to confirm that it does what it should, but you also want to know what else might happen, she says.

The researchers trained Metabolite Translator to predict metabolites through any enzyme, but measured its success against the existing rules-based methods that are focused on the enzymes in the liver. These enzymes are responsible for detoxifying and eliminating xenobiotics, like drugs, pesticides, and pollutants. However, metabolites can form through other enzymes as well.

Our bodies are networks of chemical reactions, says graduate student and lead author Eleni Litsa. They have enzymes that act upon chemicals and may break or form bonds that change their structures into something that could be toxic, or cause other complications. Existing methodologies focus on the liver because most xenobiotic compounds are metabolized there. With our work, were trying to capture human metabolism in general.

The safety of a drug does not depend only on the drug itself but also on the metabolites that can be formed when the drug is processed in the body, Litsa says.

The rise of machine learning architectures that operate on structured data, such as chemical molecules, make the work possible, she says.

Transformer was introduced in 2017 as a sequence translation method that has found wide use in language translation and is based on SMILES (for simplified molecular-input line-entry system), a notation method that uses plain text rather than diagrams to represent chemical molecules.

What were doing is exactly the same as translating a language, like English to German, Litsa says.

Due to the lack of experimental data, the lab used transfer learning to develop Metabolite Translator. They first pre-trained a Transformer model on 900,000 known chemical reactions and then fine-tuned it with data on human metabolic transformations.

The researchers compared Metabolite Translator results with those from several other predictive techniques by analyzing known SMILES sequences of 65 drugs and 179 metabolizing enzymes.

Though they trained Metabolite Translator on a general dataset not specific to drugs, it performed as well as commonly used rule-based methods that have been specifically developed for drugs. But it also identified enzymes not commonly involved in drug metabolism and not found by existing methods.

We have a system that can predict equally well with rule-based systems, and we didnt put any rules in our system that require manual work and expert knowledge, Kavraki says. Using a machine learning-based method, we are training a system to understand human metabolism without the need for explicitly encoding this knowledge in the form of rules. This work would not have been possible two years ago.

Rice University and the Cancer Prevention and Research Institute of Texas supported the research.

Source: Rice University

Read the rest here:
AI tool could predict how drugs will react in the body - Futurity: Research News

NIH to support 85 new grants featuring high-risk, high-reward research – National Institutes of Health

Posted on by

News Release

Tuesday, October 6, 2020

The 2020 Directors Awards will feature highly innovative biomedical research by investigators at all career stages.

The National Institutes of Health has awarded 85 grants through its High-Risk, High-Reward Research (HRHR) Program that will fund highly innovative and unusually impactful biomedical or behavioral research proposed by extraordinarily creative scientists. Examples of supported research include understanding the role of neighborhoods on urban substance abuse, brain-machine interfaces that allow learning by both brain and machine, engineering multi-organs in a dish, and exploiting latent immune pathways to treat disease. The 85 awards total approximately $251 million over five years, pending available funds.

The High-Risk, High-Reward Research program catalyzes scientific discovery by supporting research proposals that, due to their inherent risk, may struggle in the traditional peer-review process despite their transformative potential. Program applicants are encouraged to think outside the box and to pursue trailblazing ideas in any area of research relevant to the NIHs mission to advance knowledge and enhance health.

The breadth of innovative science put forth by the 2020 cohort of early career and seasoned investigators is impressive and inspiring," said NIH Director Francis S. Collins, M.D., Ph.D. I am confident that their work will propel biomedical and behavioral research and lead to improvements in human health.

The High-Risk, High-Reward Research Program is part of the NIH Common Fund, which oversees programs that pursue major opportunities and gaps throughout the research enterprise that are of great importance to NIH and require collaboration across the agency to succeed. The High-Risk, High-Reward Research program manages the following four awards, including two awards aimed specifically to support researchers in the early stages of their careers:

NIH issued10 Pioneer awards,53 New Innovator awards,nine Transformative Research awards, and 13 Early Independence awards for 2020. Funding for the awards comes from the NIH Common Fund; Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Cancer Institute; National Human Genome Research Institute; National Institute of Biomedical Imaging and Bioengineering; National Institute of Dental and Craniofacial Research; National Institute of General Medical Sciences; National Institute of Mental Health; National Institute of Neurological Disorders and Stroke; and National Institute on Aging.

About the NIH Common Fund: The NIH Common Fund encourages collaboration and supports a series of exceptionally high-impact, trans-NIH programs. Common Fund programs are managed by the Office of Strategic Coordination in the Division of Program Coordination, Planning, and Strategic Initiatives in the NIH Office of the Director in partnership with the NIH Institutes, Centers, and Offices. More information is available at the Common Fund website:https://commonfund.nih.gov.

About the National Institutes of Health (NIH):NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit http://www.nih.gov.

NIHTurning Discovery Into Health

###

More:
NIH to support 85 new grants featuring high-risk, high-reward research - National Institutes of Health

Phenylalanine Market: Qualitative analysis of the leading players and competitive industry scenario | Ajinomoto, Daesang, KYOWA, Evonik, Amino GmbH -…

Posted on by

Phenylalanine Market Scenario 2020-2026:

The Global Phenylalanine market exhibits comprehensive information that is a valuable source of insightful data for business strategists during the decade 2014-2026. On the basis of historical data, Phenylalanine market report provides key segments and their sub-segments, revenue and demand & supply data. Considering technological breakthroughs of the market Phenylalanine industry is likely to appear as a commendable platform for emerging Phenylalanine market investors.

This Phenylalanine Market Report covers the manufacturers data, including shipment, price, revenue, gross profit, interview record, business distribution, etc., these data help the consumer know about the competitors better.

Get Sample Report: https://grandviewreport.com/sample/58514

The complete value chain and downstream and upstream essentials are scrutinized in this report. Essential trends like globalization, growth progress boost fragmentation regulation & ecological concerns. This Market report covers technical data, manufacturing plants analysis, and raw material sources analysis of Phenylalanine Industry as well as explains which product has the highest penetration, their profit margins, and R&D status. The report makes future projections based on the analysis of the subdivision of the market which includes the global market size by product category, end-user application, and various regions.

Topmost Leading Manufacturer Covered in this report:Ajinomoto, Daesang, KYOWA, Evonik, Amino GmbH, Maidan Group, Livzon Group, Sino Sweet, Bafeng Pharmaceutical, Jinghai Amino Acid, JIRONG PHARM, Jiahe Biotech, Siwei Amino Acid, Xiyue Pharmaceutical, Dongchen Bioengineering

Product Segment Analysis: Food Grade, Pharmaceutical Grade, Feed Grade

Application Segment Analysis:

FoodMedicalFeed

Get Discount @ https://grandviewreport.com/discount/58514

Regional Analysis For PhenylalanineMarket

North America(the United States, Canada, and Mexico)Europe(Germany, France, UK, Russia, and Italy)Asia-Pacific(China, Japan, Korea, India, and Southeast Asia)South America(Brazil, Argentina, Colombia, etc.)The Middle East and Africa(Saudi Arabia, UAE, Egypt, Nigeria, and South Africa)

Market Synopsis:The market research report consists of extensive primary research, as well as an in-depth analysis of the qualitative and quantitative aspects by various industry specialists and professionals, to gain a deeper insight into the market and the overall landscape.

The objectives of the report are:

To analyze and forecast the market size of PhenylalanineIndustry in theglobal market. To study the global key players, SWOT analysis, value and global market share for leading players. To determine, explain and forecast the market by type, end use, and region. To analyze the market potential and advantage, opportunity and challenge, restraints and risks of global key regions. To find out significant trends and factors driving or restraining the market growth. To analyze the opportunities in the market for stakeholders by identifying the high growth segments. To critically analyze each submarket in terms of individual growth trend and their contribution to the market. To understand competitive developments such as agreements, expansions, new product launches, and possessions in the market. To strategically outline the key players and comprehensively analyze their growth strategies.

View Full Report @ https://grandviewreport.com/industry-growth/Phenylalanine-Market-58514

At last, the study gives out details about the major challenges that are going to impact market growth. They also report provides comprehensive details about the business opportunities to key stakeholders to grow their business and raise revenues in the precise verticals. The report will aid the companys existing or intend to join in this market to analyze the various aspects of this domain before investing or expanding their business in the Phenylalanine markets.

Contact Us:Grand View Report(UK) +44-208-133-9198(APAC) +91-73789-80300Email : [emailprotected]

More here:
Phenylalanine Market: Qualitative analysis of the leading players and competitive industry scenario | Ajinomoto, Daesang, KYOWA, Evonik, Amino GmbH -...